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the combination of radiotherapy and DAO, in primary cultures 
from glioblastoma. 
 
Material and Methods: We have used primary cultures and 
stablished cell lines from patients with glioblastoma. 
Recombinant DAO carrying the C-terminal domain of the 
major lytic amidase (CLytA) specific for binding to choline 
was inmobilized to magnetic nanoparticles having a 
magnetite core covered with Diethylaminoethyl (DEAE) 
cellulose. Primary cultures were irradiated at 7 and 15 Gy. 
After irradiation, cultures were treated in the absence or in 
the presence of DAO (free or inmovilized in nanoparticles) 
and D-alanine (enzyme substrate). After irradiation, cells 
were harvested and cell cycle distribution was determined by 
flow citometry. 
 
Results: We have demonstrated in primary cultures from 
glioblastoma, that the treatment with DAO after irradiation, 
potentiates dramatically the effect of the radiation alone, 
increasing especially the percentage of cells in the sub-G1 
phase, an indicator of cell death. Some representative results 
are included in the attached file. DAO inmovilized in 
magnetic nanoparticles is more effective than free enzyme, 
since DAO is more stable at 37ºC inmovilized in nanoparticles.  
 
Conclusion: The combination of radiotherapy and enzymatic 
therapy with DAO based on the nanotechnology, induce an 
increase in cell death when it is compared with radiotherapy 
alone. 
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Purpose or Objective: There are several indications that the 
Hedgehog (Hh) pathway could be a potential target for 
radiosensitization. Furthermore, a link between Hh signaling 
and the cellular energy metabolism has been described 
recently, more specific at the level of AMP-activated protein 
kinase (AMPK). Activation of AMPK, in turn, has also been 
shown to result in radiosensitization. Therefore, it seems 
worthwhile to explore whether the combination of Hh 
signaling inhibitors and AMPK activators such as metformin 
could further increase the response to radiotherapy. This 
combination strategy is being tested in prostate cancer (PCa) 
cells, as there is increasing evidence that the Hh pathway 
plays an important role in the development as well as 
progression to more advanced disease stages of PCa. 
 
Material and Methods: Three PCa cell lines (PC3, DU145, 
22Rv1) were treated for 72h with the SMO inhibitor GDC-0449 
(1µM, 10µM) or GLI1/2 inhibitor GANT61 (1µM, 10µM), with or 
without metformin (5mM). The effects on cell survival, 
proliferation and radiation sensitivity were investigated by 
means of Sulforhodamine B (SRB) assays, Bromodeoxyuridine 
(BrdU) assays and colony assays. The effects on gene and 
protein expression (qRT-PCR/Western blotting), cell cycle 
distribution (flow cytometry, PI staining) and DNA repair 
(flow cytometry, γH2AX) were also examined, both in the 
absence and presence of ionizing radiation (4Gy). 
 
Results: GDC-0449 on its own did not significantly affect cell 
proliferation, survival or radiation sensitivity of any of the 
PCa cell lines tested. Treatment with 10µM GANT61 on the 
other hand did result in a significant reduction of cell survival 
in all cell lines and induced radiosensitization in the 22Rv1 
cells (DEF(SF0.5)=1.39±0.11, p=0.002) (Fig 1A). The latter 
could be ascribed to the drug’s effect on apoptosis (Fig1B). 
Similar results as for GANT61 were observed after metformin 
monotherapy (DEF(SF0.5)=1.36±0.08, p=0.012). Moreover, 
metformin induced a significant downregulation of GLI1, both 
at the gene and protein expression level. While the 
combination of metformin and GDC-0449 resulted in no 
additional effects, addition of metformin to GANT61 further 
enhanced the radiosensitization effects as induced by single 
agent treatment in the 22Rv1 cells. 
 
 
 
Conclusion: The GLI1/2 inhibitor GANT61 as well as 
metformin induced radiosensitization in the 22Rv1 PCa cells. 
The combination of both agents further enhanced the 
response to radiotherapy, indicating that this might be a 
more powerful radiosensitization strategy as compared to 
either agent alone. Investigations are currently ongoing to 
explore the underlying working mechanisms. 
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Purpose or Objective: The checkpoint kinases ATR and CHK1 
are considered promising targets for cancer treatment due to 
their roles in regulation of the S and G2 checkpoints and in 
the repair of DNA double strand breaks through homologous 
recombination. Interestingly, severe levels of hypoxia (<0.1% 
O2) have been shown to activate ATR/CHK1 signaling, which 
could likely make hypoxic cancer cells sensitive to inhibitors 
of these kinases. The aim of this project is to explore 
whether inhibition of ATR or CHK1 could be used to 
selectively target hypoxic cancer cells, both in combination 
with ionizing radiation and on its own. 
 
Material and Methods: Cancer cell lines U2OS, HCT116, 
H460, A549 and H1975 were treated with inhibitors of ATR 
(VE821, VE822) or Chk1 (AZD7762, UCN01) in the absence and 
presence of hypoxia (InVivo2 hypoxia chamber) and X-ray-
irradiation. Cells were analyzed by flow cytometry, 
immunoblotting and clonogenic survival assays. 
 
Results: We previously measured clonogenic survival, cell 
cycle distribution and activation of DNA damage signaling 
pathways in U2OS and HCT116 cancer cells at different 
oxygen concentrations (21%, 0.2% and 0.0% O2) in 
combination with the CHK1 inhibitors UCN-01 and AZD7762 
and ionizing radiation. We found that hypoxia alone did not 
alter the sensitivity to CHK1 inhibitors, but inhibition of CHK1 
after reoxygenation following periods of extreme hypoxia 
(0.0% O2) did result in decreased clonogenic survival and an 
increased fraction of γ-H2AX positive cells. Hypoxic cells 
were also found to be radiosensitized at least to the same 
extent as normoxic cells by CHK1 inhibition. Currently we are 
performing similar studies in lung cancer cell lines H460, 
A549 and H1975 treated with the ATR inhibitors VE821 and 
VE822. We have found that the number of γ-H2AX positive 
cells after ATR inhibition was higher in cells incubated at 
hypoxia (0.0% O2, 20h) compared to normoxia (21% O2). The 
ATR inhibitors also abrogated the radiation-induced G2 
checkpoint. Clonogenic survival assays are ongoing. 
 
Conclusion: These studies help determine the potential of 
using inhibitors of ATR and CHK1 to eradicate radioresistant 
hypoxic cancer cells 
 
 
